托珠单抗与 COVID-19：2120 例重症患者的荟萃分析及其对临床试验方法学的影响。
Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies.
机构信息
Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan
Research Department, Fatima Jinnah Medical University, Lahore, Pakistan
出版信息
Turk J Med Sci. 2021 Jun 28;51(3):890-897. doi: 10.3906/sag-2010-131.
BACKGROUND/AIM: Since the outbreak of the COVID-19, numerous therapies to counteract this severe disease have emerged. The benefits of Tocilizumab for severely infected COVID-19 patients and the methodologies of ongoing clinical trials are explored.
MATERIALS AND METHODS
A systematic search adhering to PRISMA guidelines was conducted in PubMed, Cochrane Central, medRxiv, and bioRxiv using the following keywords: “Tocilizumab,” “Actemra,” “COVID-19.” An additional subsearch was conducted on Clinicaltrials.gov to locate ongoing tocilizumab trials.
RESULTS
A total of 13 studies were included in the meta-analysis comprising 2120 patients. The treatment group had lower mortality compared to the control group (OR = 0.42, 95% CI = 0.26 to 0.69, P = 0.0005, I2 = 55%). A descriptive analysis of 50 registered trials was conducted.
CONCLUSION
This review meta-analyzed the therapeutic benefits of tocilizumab in COVID-19 patients with severe disease for mortality, mechanical ventilation, and the characteristics of COVID-19 registered trials.
背景/目的：自 COVID-19 爆发以来，已经出现了许多针对这种严重疾病的治疗方法。本研究旨在探讨托珠单抗对严重感染 COVID-19 患者的疗效，以及正在进行的临床试验的方法。
材料和方法
本研究通过系统检索 PubMed、Cochrane Central、medRxiv 和 bioRxiv 数据库，采用“Tocilizumab”“Actemra”“COVID-19”等关键词，遵循 PRISMA 指南进行检索，并在 Clinicaltrials.gov 上进行了补充检索，以查找正在进行的托珠单抗临床试验。
结果
共有 13 项研究被纳入荟萃分析，包括 2120 名患者。与对照组相比，治疗组的死亡率较低（OR = 0.42，95%CI = 0.26 至 0.69，P = 0.0005，I2 = 55%）。对 50 项已注册的临床试验进行了描述性分析。
结论
本综述荟萃分析了托珠单抗治疗严重 COVID-19 患者的疗效，包括死亡率、机械通气以及 COVID-19 注册试验的特点。
Zotero 插件